Targovax plans checkpoint combo trial after posting early data on oncolytic virus

FierceBiotech | January 22, 2020

Targovax plans checkpoint combo trial after posting early data on oncolytic virus
Targovax has shared data from an early-phase trial that administered ONCOS-102 to mesothelioma patients. The response rate was lower in the ONCOS-102 arm than in the control cohort, but Targovax saw positives elsewhere, leading it to outline plans to pair the drug with a checkpoint inhibitor. ONCOS-102 is an adenovírus-based cancer therapy that Targovax thinks can improve on treatment options available to patients with pleural mesothelioma, a type of cancer that affects the lining of the lungs. That belief is underpinned by preclinical evidence that ONCOS-102 directly kills cancer cells and triggers an innate immune response.

Spotlight

The scope of the journal includes the research, industrial and commercial aspects of biotechnology, in areas such as: Healthcare and Pharmaceuticals; Food and Agriculture; Biofuels; Genetic Engineering and Molecular Biology; Genomics and Synthetic Biology; Nanotechnology; Environment and Biodiversity; Biocatalysis; Bioremediation; Process engineering.


Other News

Selected Notes From Wall Street Analysts On Applied DNA Sciences, Inc. (APDN)

US Post News | April 16, 2020

On Wednesday, shares of Applied DNA Sciences, Inc. (NASDAQ:APDN) marked $5.76 per share versus a previous $4.55 closing price. With having a 26.59% gain, an insight into the fundamental values of Applied DNA Sciences, Inc., investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. APDN showed a rise of 37.47% within its YTD performance, with highs and lows between $2.52 – $33.60 during the period of 52 weeks, compared to the simple moving average of -26.60% in the period of the last 200 days. Maxim Group equity researchers changed the status of Applied DNA Sciences, Inc. (NASDAQ: APDN) shares to a “Buy” rating in the report published on November 14th, 2016. Other analysts, including Maxim Group, also published their reports on APDN shares. Maxim Group repeated the rating from the previous report, marking APDN under “Buy” rating, in the report published on May 13th, 2016. Additionally, APDN shares got another “Buy” rating from Maxim Group, setting a target price of $13 on the company’s shares, according to the report published in October 8th, 2015.

Read More

AVM Biotechnology has FDA Approval for Clinical Trials for Promising New Cancer Treatment

PR Newswire | April 14, 2020

Seattle's AVM Biotechnology announces clinical trial approval for AVM0703, an exciting new drug to treat terminal no-option Non-Hodgkins Lymphoma, Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia. We are seeking patients to begin Phase I/II trials. Compassionate use will be considered under US FDA guidelines. More information can be found here: clinicaltrials.gov. AVM0703 works by supercharging and mobilizing the immune cells within all of us. When a patient is treated with AVM0703 supercharged immune cells (natural killer T-cells, gamma delta T cells and dendritic cells) invade and destroy tumors more powerfully than untreated immune cells. Because of its mechanism of action, AVM0703 is also a potential treatment for viruses like COVID-19. Within 2-7 days after treatment a patient will know whether they have responded. If there is no response that leaves other treatment options open.

Read More

Coronavirus Testing Kits Market is Booming Worldwide, BioMednomics, GenMark Diagnostics, Getein Biotech

openPR.com | April 13, 2020

Advance Market Analytics released the research report of Global Coronavirus Testing Kits Market, offers a detailed overview of the factors influencing the global business scope. Global Coronavirus Testing Kits Market research report shows the latest market insights with upcoming trends and breakdown of the products and services. The report provides key statistics on the market status, size, share, growth factors of the Global Coronavirus Testing Kits. This Report covers the emerging player's data, including: competitive situation, sales, revenue and global market share of top manufacturers are MyLab (India), Altona Diagnostics (Germany), BioMednomics (United States), Getein Biotech (China), Sensing Self Ltd (Singapore), AmonMed Biotechnology Co (China), Biomaxima (Poland), CTK Biotech (United States), Vivacheck Lab (China), Hangzhou Biotest Biotech (China), Wondfo (China), GenMark Diagnostics, Inc. (United States), XCR Diagnostics (United States), SensDx S.A.

Read More

Ancient Submerged Cypress Forest Could Hold Potential For New Medicines, Biotechnology

IFLScience | April 09, 2020

A 60,000-year-old forest submerged in the Gulf of Mexico may hold potential for the development of new medicines and biotechnology in the future – and scientists are only just beginning to understand what other secrets it may hold. Along the banks of a river in Alabama was once a flourishing bald cypress forest. As the trees grew and died, they eventually fell and become buried in peat and sediment. Over time, sea levels rose and covered the ancient forest far beneath the surface of the ocean in what would eventually become a unique and isolated habitat for marine organisms. Intensifying storm systems have recently disturbed the seafloor to expose these large logs, which have become a bit of a reef-like marine ecosystem home to wood-eating “shipworms,” which are technically clams (Teredinid bivalve). These shipworms are also known as the “termites of the sea” – a nickname they’ve received thanks to their ability to convert wood into animal tissue that forms the foundation of the deep-sea food chain.

Read More

Spotlight

The scope of the journal includes the research, industrial and commercial aspects of biotechnology, in areas such as: Healthcare and Pharmaceuticals; Food and Agriculture; Biofuels; Genetic Engineering and Molecular Biology; Genomics and Synthetic Biology; Nanotechnology; Environment and Biodiversity; Biocatalysis; Bioremediation; Process engineering.

Resources